Allogene Therapeutics, Inc.
ALLO Healthcare Biotechnology
Allogene Therapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $22,000.00, down 76.8% from fiscal 2023. In the quarter to June 2026, revenue grew 20,990.9%, EPS grew 43.5% and free cash flow grew 17.7%, each against the same quarter a year earlier.
Follow ALLO
A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|---|
Cash and Short Term Investments |
250.21 | 292.48 | 448.70 | 517.32 | 457.30 | 827.91 | 530.53 | 459.38 | — |
Total current assets |
257.75 | 303.39 | 459.12 | 528.82 | 471.32 | 845.13 | 544.58 | 467.98 | — |
Property, Plant, Equpment (Net) |
72.84 | 86.06 | 99.48 | 112.84 | 122.99 | 118.84 | 56.45 | 8.60 | — |
Long-Term Investments |
8.04 | 80.67 | 3.65 | 76.47 | 382.38 | 207.95 | 63.21 | 261.97 | — |
Goodwill and Intangible Assets (Total) |
— | — | — | — | — | — | 0.15 | 0.75 | — |
Long-term assets (Other) |
37.39 | 33.39 | 16.90 | 19.86 | 16.11 | 14.62 | 8.92 | 1.54 | — |
Total non-current assets |
158.16 | 245.32 | 183.72 | 292.76 | 579.50 | 382.70 | 173.23 | 305.87 | — |
Total Assets |
415.91 | 548.71 | 642.84 | 821.58 | 1,050.83 | 1,227.83 | 717.80 | 773.86 | — |
Accounts Payable |
4.27 | 5.39 | 5.90 | 13.89 | 10.26 | 10.39 | 9.25 | 12.34 | — |
Accrued Expenses |
28.24 | 30.13 | 31.18 | 39.74 | 37.50 | 44.94 | 23.83 | 17.12 | 0.00 |
Current Revenue (Deferred) |
— | — | 0.09 | 0.10 | 0.16 | 38.99 | — | — | — |
Total current liabilities |
32.51 | 35.52 | 37.08 | 53.73 | 47.91 | 94.32 | 33.08 | 29.46 | 0.00 |
Non-current Liabilities (Other) |
15.80 | 7.76 | 5.18 | 5.85 | 7.79 | 3.08 | 4.35 | 6.78 | — |
Total non-current liabilities |
90.85 | 91.01 | 93.53 | 100.97 | 77.72 | 53.89 | 55.70 | 41.23 | — |
Total liabilities |
123.36 | 126.53 | 130.60 | 154.70 | 125.63 | 148.21 | 88.78 | 70.69 | 0.00 |
Additional Paid In Capital |
2,302.75 | 2,241.88 | 2,075.25 | 1,911.63 | 1,822.18 | 1,725.55 | 1,023.88 | 914.27 | — |
Common Stock (Net) |
0.23 | 0.21 | 0.17 | 0.14 | 0.14 | 0.14 | 0.12 | 0.12 | 0.03 |
Retained Earnings |
(2,010.71) | (1,819.82) | (1,562.23) | (1,234.97) | (894.55) | (646.34) | (396.12) | (211.53) | (0.02) |
Shareholders Equity (Other) |
— | — | — | — | — | — | — | — | 0.00 |
Common Equity (Total) |
292.54 | 422.18 | 512.23 | 666.88 | 925.20 | 1,079.62 | 629.02 | 703.16 | 0.00 |
Shareholders Equity (Total) |
292.54 | 422.18 | 512.23 | 666.88 | 925.20 | 1,079.62 | 629.02 | 703.16 | 0.00 |
Shareholders Equity and Liabilities (Total) |
415.91 | 548.71 | 642.84 | 821.58 | 1,050.83 | 1,227.83 | 717.80 | 773.86 | — |
Shares (Common) |
229.41 | 212.21 | 168.64 | 144.44 | 142.62 | 140.47 | 124.27 | 121.48 | 26.25 |
Shareholders Equity (Tangible) |
292.54 | 422.18 | 512.23 | 666.88 | 925.20 | 1,079.62 | 628.87 | 702.41 | 0.00 |
Net Debt |
(250.21) | (292.48) | (448.70) | (517.32) | (457.30) | (827.91) | (530.53) | (459.38) | — |
Total Debt |
— | — | — | 101.00 | 73.00 | 54.00 | 51.00 | 34.00 | — |